APRIL 16-18, 2019

BOSTON, MA USA

The 6th Annual Translational Microbiome Conference is Coming Back to Boston in April 2020. 

Please check back in the coming weeks for additional details.

The Official Blog of the Annual Translational Microbiome Conference

The official blog of the Annual Translational Microbiome Conference provides readers with information, insight and analysis regarding the microbiome.

Interview with Mollie Roth: Executive Director of The Microbiome Coalition (TMBC)

 

Interview with Mollie Roth, JD

Executive Director of The Microbiome Coalition (TMBC)

 

What is The Microbiome Coalition and what’s its goal?

The Microbiome Coalition (TMBC) represents a variety of commercial entities working toward commercial success in the microbiome field, united by their desire to promote greater public understanding of the role of the microbiome in human health and wellness, and the desire to advance appropriate regulation, needed investment and required infrastructure.

Recognizing that a shift in how microbiome based medicine and research is implemented will not happen simply because a body of scientific evidence suggests it should, TMBC has identified key goals to support and advance the industry, including: Education, Regulatory Engagement and Standards. You can learn more about what we are doing on all three fronts at http://www.themicrobiomecoalition.com/

 

How did TMBC come to be formed? 

Although I started my career as a litigator for the pharmaceutical industry, I have always had an affinity for making business run better. I spent 10 years working with a precision medicine consulting company helping pharma drug development teams understand how to co-develop and launch companion diagnostics.

In early 2013, I started working as a consultant in the microbiome space and became interested not only in the vast body of research that was happening across multiple industries – pharmaceutical, diagnostic, consumer products and nutrition – but in the challenges for companies to become a commercial success. Many of the hurdles and challenges this industry faces mirror exactly the experience in the precision medicine field – an unclear regulatory path, unclear business models, a lack of standards, differing reference databases among others.

It was my opinion, based on my experience in the precision medicine field, that a coalition of companies in this space could better address and overcome these challenges than any one company could. Thankfully the founding companies agreed with me and TMBC was born.

 

You said one of TMBC's goals pertains to standards, is there a problem with standards in the microbiome space?

In scientific research, standards allow for and ensure quality in research and the generation of quality evidence that can be compared across researchers and companies. Absent uniform standards, the quality of scientific research can be uneven and lacking in credibility, making it difficult to make confident, concrete assertions or predictions regarding evidence for improving practice or consumer outcomes.

For example, in the precision medicine space, we saw the lack of standards cause issues when it became apparent that there were no standardized practices for how samples being used to generate clinical data for diagnostic tests were handled. There are a number of groups already hard at work on two distinct standards issues in the microbiome space – how samples are handled and sequenced as well as how the vast volume of information generated in this space is processed. 

TMBC will serve as a clearinghouse for these activities already underway and will bring these disparate groups to the table to ensure they are engaging with each other so the industry ends up with a set of conformed standards, rather than numerous sets of non-interoperable standards.

 

What companies formed TMBC?

The founding companies are a visionary set of innovators who quickly understood the need for a coalition of companies working toward commercial success in the microbiome space and have provided seed support and substantial resources to get the coalition off the ground. They include AOBiome, Whole Biome, CosmosID, Abbott Nutrition, The Mayo Clinic, Diversigen and Second Genome.

 

How important are collaborations in the microbiome space?

 As incredibly important as they are in any area of new scientific research!

There are literally hundreds of small startup companies making incredibly exciting discoveries with regard to the microbiome, but without the resources or global reach to complete their research or get products approved and launched. Collaborations with larger companies, carefully crafted to ensure a win-win, are not only vital but imperative to move this space forward.

Further, now that we are a few years into the “age of the microbiome” we are starting to see a convergence between microbiome therapies and precision medicine, as companies consider how patients might need to be stratified based on their microbiome to determine who best to treat. The business models of how pharma and diagnostic companies can best collaborate and work together will continue to be vitally important as these two spaces continue to merge.

 

Is membership in TMBC open and to whom?

Membership in TMBC is open and we welcome any company, association or individual with an interest in advancing the commercial viability of microbiome based therapies, diagnostics, consumer or nutrition products to address and improve human health and wellness. You can learn more about membership options at http://www.themicrobiomecoalition.com/become-a-member/

 

The Medium is the Message
Tailoring Microbiome Interventions: The Intersecti...

Related Posts

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

Arrowhead Publishers & Conferences
PO Box 96
7730 Laredo Drive, #96
Chanhassen, MN 55317
866-945-0263
enquiries@arrowheadpublishers.com

PRIVACY POLICY

NEW EVENT JUST ANNOUNCED

The Microbiome-Vaccine Summit: Microbiome-Mediated Immunity and the Future of Vaccines

Dates and Location: September 2019 | London, United Kingdom

Microbes in the gut have been found to exert profound control over the immune system. The role of the microbiome in modulating the immune response has already been substantially researched with numerous correlations between the microbiome’s immune effects and disease hypothesized and being explored. One exciting area of inquiry is the potential for the microbiome to play a substantial role in vaccine response. This area of exploration includes:

♦ Its potential to change how patients respond to checkpoint inhibition therapy for metastatic melanoma
♦ Correlations between the efficacy of the rotavirus and geographic differences in the gut biome
♦ How the antibiotic-mediated dysbiotic gut microbiome may actually mount a strong immune response to the seasonal flu vaccine
♦ And the gut-lung axis, or the role of the microbiome in the meteoric rise of asthma
♦ And even the possibility of explaining why some children experience adverse reactions to vaccinations, and why our current vaccine protocol starting within 12 hours of birth does not properly factor gut microbiota as crucial to immune response.

An extension of the highly successful Arrowhead Translational Microbiome Conference held every April in Boston, join us for this first event in our Translational Microbiome Spotlight series, where we bring together industry and academic experts considering the interface between the microbiome and vaccines in a one day, highly interactive roundtable forum.

CLICK HERE to request more information. If you are interested in speaking or sponsorship opportunities, please email This email address is being protected from spambots. You need JavaScript enabled to view it..